OTC Statin Dispensing Through Algorithmic Eligibility Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for systems and methods to safely and effectively qualify human subjects for over-the-counter provision of statin pharmaceutical compositions to treat or prevent heart disease, as current attempts to switch statins from prescription-only to OTC status have failed due to inappropriate patient selection and medication compliance issues.
Innovation Solution
A method involving an algorithm that runs subject information against a plurality of filters to assess eligibility, providing warnings and ensuring acknowledgment before authorizing the provision of statin pharmaceutical compositions, including rosuvastatin, through a fulfillment process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If statins are made available over the counter to increase accessibility, then patient access to cholesterol-lowering medications is improved, but inappropriate patient selection and adverse effects increase
Solution Approach 1:
The patent implements preliminary actions by requiring patients to complete a comprehensive questionnaire and undergo algorithm-based assessment before obtaining statin medication. The system performs preliminary screening for contraindications (such as active liver disease, pregnancy, and drug interactions) and risk factor evaluation before authorization, ensuring only appropriate candidates receive the medication.
Solution Approach 2:
The system incorporates feedback mechanisms through continuous monitoring of patient responses to questionnaire updates, algorithmic re-evaluation of eligibility status, and requirement for acknowledgment of warnings. The algorithm dynamically adjusts assessment based on patient-provided information and provides feedback through warning messages that must be acknowledged before medication dispensing.
2Reliability
If comprehensive patient assessment algorithms are implemented to improve selection accuracy, then patient safety is improved, but system complexity and implementation cost increase
Solution Approach 1:
The assessment algorithm is segmented into distinct evaluation modules: contraindication screening (checking for absolute prohibitions like active liver disease or pregnancy), risk factor assessment (evaluating cholesterol levels, age, and comorbidities), and warning generation (identifying moderate concerns requiring acknowledgment). This modular segmentation makes the complex system more manageable and easier to implement.
Solution Approach 2:
The patent introduces an intermediary computer-based assessment system that mediates between the patient and the statin medication. This intermediary algorithm acts as a filter, processing patient questionnaire data and determining eligibility without requiring direct physician intervention for each assessment, thereby reducing overall system complexity while maintaining accuracy.
3Reliability
If multiple assessment filters are applied to evaluate patient eligibility, then identification of contraindications is improved, but time required for assessment increases
Solution Approach 1:
The system performs preliminary filtering by first checking for absolute contraindications (first plurality of filters) before proceeding to risk factor assessment (second plurality of filters). This staged approach ensures that time-consuming detailed assessments are only performed on patients who pass the initial contraindication screen, reducing overall assessment time while maintaining thoroughness.
Solution Approach 2:
The algorithm applies partial action by implementing multiple filter levels where not all filters require full evaluation for every patient. The system uses excessive filtering (multiple layers of assessment) for contraindications but can streamline risk factor evaluation based on individual patient responses, balancing thoroughness with time efficiency.
Data Source
AI summary
A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.